Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Prevalence and risk factors associated with resistance-associated mutations to etravirine in a cohort of perinatally HIV-infected children.

Contreras GA, Bell CS, Del Bianco GP, Pérez N, Kleinosky MT, Murphy JR, Heresi GP.

J Antimicrob Chemother. 2013 Oct;68(10):2344-8. doi: 10.1093/jac/dkt198.

PMID:
23732699
2.

Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics.

Martins AN, Arruda MB, Aleixo AW, Pires AF, Greco DB, de M Brindeiro R, Tanuri A.

J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 3:S193-6. doi: 10.1097/QAI.0b013e31821e9cf6.

PMID:
21857317
3.

Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.

Bunupuradah T, Ananworanich J, Chetchotisakd P, Kantipong P, Jirajariyavej S, Sirivichayakul S, Munsakul W, Prasithsirikul W, Sungkanuparph S, Bowonwattanuwong C, Klinbuayaem V, Petoumenos K, Hirschel B, Bhakeecheep S, Ruxrungtham K.

Antivir Ther. 2011;16(7):1113-21. doi: 10.3851/IMP1906.

PMID:
22024527
4.

Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.

Lapadula G, Calabresi A, Castelnuovo F, Costarelli S, Quiros-Roldan E, Paraninfo G, Ceresoli F, Gargiulo F, Manca N, Carosi G, Torti C.

Antivir Ther. 2008;13(4):601-5.

PMID:
18672539
5.

Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.

Llibre JM, Santos JR, Puig T, Moltó J, Ruiz L, Paredes R, Clotet B.

J Antimicrob Chemother. 2008 Nov;62(5):909-13. doi: 10.1093/jac/dkn297.

PMID:
18653487
6.

Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.

Kiertiburanakul S, Wiboonchutikul S, Sukasem C, Chantratita W, Sungkanuparph S.

J Clin Virol. 2010 Apr;47(4):330-4. doi: 10.1016/j.jcv.2010.01.018.

PMID:
20188624
7.

Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.

Taiwo B, Chaplin B, Penugonda S, Meloni S, Akanmu S, Gashau W, Idoko J, Adewole I, Murphy R, Kanki P.

Curr HIV Res. 2010 Apr;8(3):194-8.

PMID:
20163340
8.

Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.

Marcelin AG, Descamps D, Tamalet C, Cottalorda J, Izopet J, Delaugerre C, Morand-Joubert L, Trabaud MA, Bettinger D, Rogez S, Ruffault A, Henquell C, Signori-Schmuck A, Bouvier-Alias M, Vallet S, Masquelier B, Flandre P, Calvez V; ANRS AC11 Resistance Study group..

Antivir Ther. 2012;17(1):119-23. doi: 10.3851/IMP1886.

PMID:
22267476
9.

HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.

Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Siangphoe U, Suwanlerk T, Ananworanich J; HIV-NAT 086Study Team..

HIV Med. 2010 Oct 1;11(9):565-72. doi: 10.1111/j.1468-1293.2010.00828.x.

10.
11.

Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA).

Di Vincenzo P, Rusconi S, Adorni F, Vitiello P, Maggiolo F, Francisci D, Di Biagio A, Monno L, Antinori A, Boeri E, Punzi G, Perno CF, Callegaro A, Bruzzone B, Zazzi M; Antiretroviral Resistance Cohort Analysis (ARCA) Collaborative Group..

HIV Med. 2010 Sep;11(8):530-4. doi: 10.1111/j.1468-1293.2009.00819.x.

12.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
13.

Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants.

Pereira-Vaz J, Duque V, Pereira B, Mota V, Morais C, Saraiva-da-Cunha J, Meliço-Silvestre A.

J Med Virol. 2012 Apr;84(4):551-4. doi: 10.1002/jmv.23232.

PMID:
22337292
14.

Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.

van Zyl GU, van der Merwe L, Claassen M, Zeier M, Preiser W.

J Med Virol. 2011 Oct;83(10):1764-9. doi: 10.1002/jmv.22189.

PMID:
21837793
15.

Etravirine.

Deeks ED, Keating GM.

Drugs. 2008;68(16):2357-72. doi: 10.2165/0003495-200868160-00007. Review.

PMID:
18973398
16.

The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.

Cozzi-Lepri A, Paredes, Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD; EuroSIDA in EuroCoord..

HIV Med. 2012 Jan;13(1):62-72. doi: 10.1111/j.1468-1293.2011.00943.x.

17.

Etravirine for the treatment of HIV/AIDS.

Schrijvers R.

Expert Opin Pharmacother. 2013 Jun;14(8):1087-96. doi: 10.1517/14656566.2013.787411. Review.

PMID:
23560740
18.

Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.

Schiller DS, Youssef-Bessler M.

Clin Ther. 2009 Apr;31(4):692-704. doi: 10.1016/j.clinthera.2009.04.020. Review.

PMID:
19446143
19.

HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.

Ghosn J, Chaix ML, Delaugerre C.

AIDS Rev. 2009 Jul-Sep;11(3):165-73. Review.

PMID:
19654858
20.

Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).

Scherrer AU, Hasse B, von Wyl V, Yerly S, Böni J, Bürgisser P, Klimkait T, Bucher HC, Ledergerber B, Günthard HF.

HIV Med. 2009 Nov;10(10):647-56. doi: 10.1111/j.1468-1293.2009.00756.x.

Supplemental Content

Support Center